Metformin, a first-line treatment for type 2 diabetes, activates 5′-AMP-activated protein kinase (AMPK), leading to suppression of the mammalian target of the rapamycin (mTOR) pathway and reduced tumor cell proliferation [265]. This evidence concerns the gene MTOR and type 2 diabetes mellitus.